Loading…
Recombinant ISRAA ameliorates imiquimod-induced psoriasis and knocking out Israa delays its onset
Psoriasis, an inflammatory disease, is largely mediated by T-helper 17 cytokines. We have previously identified the immune system-released activating agent ( Israa ) as a novel gene that connects the nervous and immune systems. This research aims to investigate the role of the Israa gene in psoriasi...
Saved in:
Published in: | Archives of dermatological research 2024-10, Vol.316 (9), p.661, Article 661 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Psoriasis, an inflammatory disease, is largely mediated by T-helper 17 cytokines. We have previously identified the immune system-released activating agent (
Israa
) as a novel gene that connects the nervous and immune systems. This research aims to investigate the role of the
Israa
gene in psoriasis in vivo using the imiquimod-induced psoriasis model. We established the model in C57BL/6 wildtype mice, which were then treated with 200 pg/mouse, 400 pg/mouse, or 800 pg/mouse of recombinant ISRAA compared to methotrexate. Subsequently, we also induced psoriasis in
Israa
-knockout mice to confirm the effect of
Israa
. Results consistently showed improvement in psoriasis in all groups receiving recombinant ISRAA. The 200 pg/mouse dose eliminated the disease, reduced the cutaneous release of IL-17 to one-third and TNF-α to one-sixth, increased IL-10 release to over 500 pg, completely resolved parakeratosis, decreased epidermal thickness to one-half, and reduced the expression of CD4 and neutrophil elastase in the skin (all
p
|
---|---|
ISSN: | 1432-069X 0340-3696 1432-069X |
DOI: | 10.1007/s00403-024-03410-5 |